Quietly over the past several years, spinal implant leader Sofamor Danek, (acquired by Medtronic Inc. [See Deal].
Smith & Nephew was a logical choice for Sofamor Danek, in part, because it's one of the few leading implant...
Smith & Nephew's Play in Image-Guided Surgery
Quietly over the past several years, spinal implant leader Sofamor Danek (acquired by Medtronic Inc. ) has built a leadership position in image-guided surgery (IGS). The relevance to Sofamor Danek's core spinal business is clear: through enhanced visualization and navigation, spinal surgeons can perform complex cases that were once thought impossible and do more routine surgeries more quickly and easily. Now, Medtronic Sofamor Danek and Smith & Nephew PLC are teaming up to see if the benefits of IGS can extend to more traditional orthopedic segments.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
• By
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.